Targeted therapy for chronic lymphocytic leukemia
A Quintás-Cardama, S O'Brien - Targeted oncology, 2009 - Springer
The introduction of targeted agents such as the monoclonal antibodies rituximab (anti-
CD20) and alemtuzumab (anti-CD52) has brought about a remarkable change in the …
CD20) and alemtuzumab (anti-CD52) has brought about a remarkable change in the …
Antibody therapy for chronic lymphocytic leukemia
BA Christian, TS Lin - Seminars in hematology, 2008 - Elsevier
The introduction of the monoclonal antibodies rituximab (anti-CD20) and alemtuzumab (anti-
CD52) has revolutionized the treatment of chronic lymphocytic leukemia (CLL). Both …
CD52) has revolutionized the treatment of chronic lymphocytic leukemia (CLL). Both …
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance
R Bannerji, S Kitada, IW Flinn, M Pearson… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Rituximab has clinical activity in patients with chronic lymphocytic leukemia (CLL)
and has a variety of proposed mechanisms, including apoptosis, complement-dependent …
and has a variety of proposed mechanisms, including apoptosis, complement-dependent …
Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events.
A Chanan-Khan, T Kipps… - Clinical advances in …, 2010 - europepmc.org
Chronic lymphocytic leukemia (CLL) is a B-cell leukemia mainly affecting older adults.
Historically, CLL has been regarded as an incurable disease, and treatment has been …
Historically, CLL has been regarded as an incurable disease, and treatment has been …
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic …
C Visco, S Finotto, F Pomponi, R Sartori… - American journal of …, 2013 - Wiley Online Library
Treatment of patients with B‐cell chronic lymphocytic leukemia (CLL) relapsed/refractory
(R/R) to conventional treatments is particularly challenging. The combination of …
(R/R) to conventional treatments is particularly challenging. The combination of …
[HTML][HTML] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus …
F Bosch, N Villamor, P Abrisqueta, MJ Terol… - Blood, 2010 - Elsevier
Abstract 1382 The effectiveness of rituximab maintenance in the treatment of CLL has been
investigated in a phase II clinical trial that includes two treatment parts. First, patients were …
investigated in a phase II clinical trial that includes two treatment parts. First, patients were …
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
V Goede, K Fischer, R Busch, A Engelke… - … England Journal of …, 2014 - Mass Medical Soc
Background The monoclonal anti-CD20 antibody rituximab, combined with
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …
[HTML][HTML] Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to …
DR Howard, T Munir, L McParland… - Health Technology …, 2017 - europepmc.org
Background The conventional frontline therapy for fit patients with chronic lymphocytic
leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab …
leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab …
The combination of rituximab and GM-CSF as frontline treatment for elderly patients with chronic lymphocytic leukemia
A FERRAJOLI, SM O'BRIEN, SH FADERL… - … TO DAVID GALTON, 2007 - Taylor & Francis
CLL is a disease of the elderly with 53% of the patients being 70 years or older. Despite
elderly patients representing the largest proportion of patients living with CLL, they are …
elderly patients representing the largest proportion of patients living with CLL, they are …
Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab
N Watanabe, T Takahashi, N Sugimoto… - International journal of …, 2005 - Springer
A 70-year-old woman was diagnosed with B-cell-type chronic lymphocytic leukemia (B-CLL)
in May 2001. Initial white blood cell (WBC) count was 37× 10 9/l and most of the cells were …
in May 2001. Initial white blood cell (WBC) count was 37× 10 9/l and most of the cells were …